Abitrexate Injection
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various cancers, including leukemia, lymphoma, and solid tumors; also used in autoimmune diseases such as rheumatoid arthritis and psoriasis.
Dosage (summary)
Administered as an injection; typical dosing varies based on indication, often starting at 7.5 to 15 mg per week for rheumatoid arthritis, and higher doses for cancer treatment as determined by the oncologist.
Onset of Action / Duration
Onset of action may vary; typically, therapeutic effects in autoimmune conditions may be observed within 4 to 6 weeks, while cancer treatment response may take longer.
Special Populations
- Elderly patients
- Patients with renal impairment
- Patients with liver dysfunction
- Pregnant or breastfeeding women
Pregnancy & Breastfeeding
Methotrexate is contraindicated in pregnancy due to its teratogenic effects. It is also excreted in breast milk; breastfeeding is not recommended during treatment.
Key Drug Interactions
- NSAIDs may increase the risk of methotrexate toxicity.
- Penicillins may decrease renal clearance of methotrexate.
- Sulfonamides may enhance the effects of methotrexate.
- Live vaccines should be avoided during treatment.
Contraindications
- Pregnancy
- Breastfeeding
- Severe renal impairment
- Active infections
- Liver disease
Common side effects
- Nausea and vomiting
- Mucositis
- Hematologic toxicity (e.g., leukopenia, thrombocytopenia)
- Hepatotoxicity
- Pulmonary toxicity
Counselling Points
- Advise patients to report any signs of infection, unusual bruising, or bleeding.
- Encourage adequate hydration to minimize renal toxicity.
- Inform patients about potential gastrointestinal side effects and the importance of taking folic acid supplements as prescribed.
- Discuss the importance of regular monitoring of blood counts and liver function tests.
Serious warnings
- Methotrexate can cause severe side effects; close monitoring is required.
- Patients should be advised to avoid alcohol due to the risk of liver toxicity.
- Use caution in patients with pre-existing lung disease due to the risk of pulmonary toxicity.
Important Disclaimer
The Abitrexate Injection professional information leaflet below is the property of Teva and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
